Systemic Anti-Cancer Therapy Regimen Library New Zealand Formulary

Central Nervous System Regimens

Glioblastoma Regimens

Published Sort regimens by
CNS GBM Adjuvant - lomustine and temozolomide chemoradiation Id: 506451000210107 Published date: Version: 1.0.0
506451000210107
1.0.0
23/05/2025
CNS GBM Recurrent - beVACizumab and irinotecan 125 mg/m2 Id: 264261000210107 Published date: Version: 3.0.0
264261000210107
3.0.0
24/08/2026
CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2 Id: 264371000210105 Published date: Version: 2.0.0
264371000210105
2.0.0
24/08/2026
CNS GBM Recurrent - beVACizumab and lomustine Id: 263971000210106 Published date: Version: 2.0.0
263971000210106
2.0.0
24/08/2026
CNS GBM Recurrent - beVACizumab Q2W Id: 263961000210100 Published date: Version: 2.0.0
263961000210100
2.0.0
24/08/2026
CNS GBM Recurrent - beVACizumab Q3W Id: 263951000210103 Published date: Version: 2.0.0
263951000210103
2.0.0
24/08/2026
CNS GBM Recurrent - lomustine Id: 264281000210104 Published date: Version: 1.0.0
264281000210104
1.0.0
25/04/2023
CNS GBM - temozolomide chemoradiation followed by temozolomide Id: 263911000210102 Published date: Version: 2.0.0
Components ▾
Part 1: temozolomide chemoradiation Id: 263921000210107 Published date: Version: 0.0.4
Part 2: temozolomide following chemoradiation Id: 263931000210109 Published date: Version: 0.0.7
263911000210102
2.0.0
04/07/2023

Glioma Regimens

Published Sort regimens by
CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [high grade] Id: 264251000210109 Published date: Version: 2.0.0
264251000210109
2.0.0
13/08/2023
CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [low grade] Id: 264241000210106 Published date: Version: 2.0.0
264241000210106
2.0.0
13/08/2023
CNS GLI Recurrent - temozolomide [continuous dose-intense] [high grade] Id: 264271000210101 Published date: Version: 2.0.0
264271000210101
2.0.0
13/08/2023
CNS GLI Recurrent - temozolomide [high grade] Id: 263941000210101 Published date: Version: 2.0.0
263941000210101
2.0.0
13/08/2023